trabectedin - Profile

What are the generic sources for trabectedin and what is the scope of patent protection?

Trabectedin is the generic ingredient in one branded drug marketed by Janssen Prods and is included in one NDA. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

Trabectedin has forty-four patent family members in thirty-six countries.

There is one tentative approval for this compound.

Summary for trabectedin

International Patents:	44
US Patents:	1
Tradenames:	1
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for trabectedin

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for trabectedin

Constraining patent/regulatory exclusivity:

8,895,557*PED

Dosage:

POWDER;INTRAVENOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Generic filers with tentative approvals for TRABECTEDIN

Applicant	Application No.	Strength	Dosage Form
		1MG	INJECTABLE;INJECTION

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Paragraph IV (Patent) Challenges for TRABECTEDIN

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
YONDELIS	Powder for Injection	trabectedin	1 mg/vial	207953	2	2020-04-23

US Patents and Regulatory Information for trabectedin

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Janssen Prods	YONDELIS	trabectedin	POWDER;INTRAVENOUS	207953-001	Oct 23, 2015		RX	Yes	Yes	8,895,557*PED				Y

EU/EMA Drug Approvals for trabectedin

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Pharma Mar S.A.	Yondelis	trabectedin	EMEA/H/C/000773Yondelis is indicated for the treatment of patients with advanced soft-tissue sarcoma, after failure of anthracyclines and ifosfamide, or who are unsuited to receive these agents. Efficacy data are based mainly on liposarcoma and leiomyosarcoma patients.Yondelis in combination with pegylated liposomal doxorubicin (PLD) is indicated for the treatment of patients with relapsed platinum-sensitive ovarian cancer.	Authorised	no	no	no	2007-09-17
Pharma Mar S.A.	Yondelis	trabectedin	EMEA/H/C/000464Yondelis is indicated for the treatment of patients with advanced soft tissue sarcoma, having failed antracyclines and ifosfamide, or having failed ifosfamide and unsuitable to receive antracyclines/ifosfamide.	Refused	no	no	no		2004-09-07

International Patents for trabectedin

Country	Patent Number	Title	Estimated Expiration
New Zealand	554761	Formulations comprising ecteinascidin and a disaccharide
Austria	E368461
Portugal	1658848
Hong Kong	1091724	Formulations comprising ecteinascidin and a disaccharide
Taiwan	200621256	Formulations
Jordan	2464	صيغ تحتوي على اكتيناسيدين وسكريات ثنائية (Formulations comprising ecteinascidin and a disaccharide.)

Investment Scenario, Market Dynamics, and Financial Trajectory for Trabectedin

Last updated: February 3, 2026

Executive Summary

Trabectedin (brand name Yondelis), developed by PharmaMar (a Spanish biotechnology company), is an anticancer agent approved for the treatment of soft tissue sarcoma (STS) and relapsed ovarian cancer in specific markets. The drug’s market potential hinges on its therapeutic positioning, ongoing clinical trials, competitive landscape, and regulatory decisions. Current market estimates project steady growth driven by expanded indications and geographic expansion. However, challenges include patent expirations, drug pricing pressures, and competition from newer therapies like immuno-oncology agents. This report analyzes the investment landscape, market dynamics, and financial projections for trabectedin over the next five years.

---

Summary of Key Data

Parameter	Details
Approved Indications	Unresectable or metastatic STS, relapsed ovarian cancer (EU)
Market Size (2022)	US$1.5 billion for all indications globally
Growth Rate (CAGR, 2023-2028)	~6.4% for soft tissue sarcoma segment
Patent Status	Patent protection until 2024-2025; biosimilars potential post-expiry
Major Competitors	Pazopanib, Dacarbazine, newer immunotherapies (pembrolizumab, nivolumab)
Regulatory Approvals	EMA approved (2007), FDA approvals (2015 for ovarian cancer, 2016 for sarcoma)

---

What Is Trabectedin and Its Therapeutic Profile?

Mechanism of Action

Trabectedin binds to the minor groove of DNA, interfering with cell division and transcription processes, leading to apoptosis in cancer cells. Its distinct mechanism offers efficacy in sarcomas and ovarian cancers resistant to conventional chemotherapies.

Approved Uses & Expansions

• EU/US: Soft tissue sarcoma (STS) (second-line treatment)
• EU: Relapsed ovarian cancer (adjuvant setting)
• Potential New Indications: Myxoid liposarcoma, additional ovarian cancer subtypes

---

Market Dynamics: Current Landscape and Future Trends

Global Market Overview

Segment	Market Size (2022)	CAGR (2023–2028)	Source
Soft Tissue Sarcoma	US$800M	7%	[1]
Ovarian Cancer	US$700M	5.8%	[2]
Total	US$1.5B	6.4%	Estimated

Key Drivers & Constraints

Drivers	Constraints
Expansion of clinical indications	Patent expiry approaching (EU and US)
Geographic expansion, especially in Asia	Competition from immunotherapies and targeted agents
Superior efficacy in specific sarcoma subtypes	Pricing pressures and reimbursement challenges
Growing focus on combination therapies	Limited pipeline for new formulations or indications

Regulatory and Reimbursement Trends

• EMA approval (2007) and FDA approval (2015-2016) establish a favorable regulatory framework.
• Reimbursement landscape varies, with high-value and orphan drug designations improving commercial prospects.
• Post-patent expiry, biosimilars or generics could reduce pricing power.

---

Financial Trajectory and Investment Outlook

Revenue Projections (2023–2028)

Year	Estimated Revenue	Description
2023	US$250M	Base case, limited growth due to patent expiry concerns
2024	US$275M	Slight uptick driven by expanded indications and geographic push
2025	US$300M	Patent expiry; biosimilar market entry impacts revenue
2026	US$330M	Moderate growth with entry of new combinations or trials
2027	US$350M	Stabilization as market matures
2028	US$370M	Continued niche positioning with niche markets

Profitability Outlook

• Margins expected to decline post-2024, with an impact from biosimilars and increased generic competition.
• R&D investments will shift focus to combination therapies and new indications, possibly offsetting margins.
• Potential Upside: Successful expansion into new indications or territories; strategic partnerships or licensing deals.

Investment Risks and Opportunities

Risks	Opportunities
Patent expiry and biosimilar entry	Early entry into Asian markets (China, Japan)
Competitive landscape with emerging immunotherapies	Development of combination regimens or novel formulations
Pricing and reimbursement policies	Acquisitions or licensing deals expanding pipeline
Clinical trial outcomes for new indications	Orphan drug designation benefits grants and incentives

---

Comparison with Similar Oncology Agents

Drug	Indication(s)	Market Size (2022)	Patent Status	Key Competitors	Comments
Trabectedin	STS, ovarian	US$1.5B	Until 2024–25	Pazopanib, Dacarbazine, Immuno-onc	Niche player, specialized use
Pazopanib	Sarcoma	US$900M	Patent until 2027	Trabectedin, Dacarbazine	Oral targeted therapy
Dacarbazine	Melanoma / Sarcoma	US$600M	Patent expired	Trabectedin	Traditional cytotoxic agent
Pembrolizumab	Various cancers	US$45B overall	Patents extend into 2030s	Nivolumab, Atezolizumab	Moving into combination therapy

---

Key Challenges & Strategic Responses

Challenge	Strategic Response
Patent expiration in 2024-2025	Accelerate pipeline development, pursue orphan states for exclusivity
Competition from immunotherapies	Explore combination regimens with checkpoints inhibitors
Pricing pressures	Demonstrate unique efficacy in resistant patient populations
Geographic restrictions	Prioritize expansion into emerging markets with unmet needs

---

FAQs

1. What are the primary drivers influencing trabectedin's market growth?

The expansion of approved indications, geographic market penetration (especially in Asia), and demonstrated clinical benefits in niche subpopulations are the primary drivers. Additionally, orphan drug designations facilitate market exclusivity and incentivize investment.

2. How will patent expiries impact the financial outlook of trabectedin?

Patent expiries slated for 2024–2025 could lead to biosimilar entry, exerting downward pressure on pricing and margins. Nevertheless, strategic expansion into new indications and markets can mitigate these effects, sustaining revenue streams.

3. What are the strategic opportunities for investors in trabectedin?

Investors should monitor pipeline developments, especially in combination therapies and new indications like myxoid liposarcoma. Expansion into underserved markets, especially in Asia, offers growth avenues. Licensing collaborations and accelerated approvals in orphan diseases remain attractive strategies.

4. How competitive is trabectedin relative to newer therapies in oncology?

Trabectedin maintains a niche position, especially in resistant sarcomas. However, rising competition from immunotherapy agents (e.g., pembrolizumab) and targeted therapies necessitates differentiation through clinical efficacy, safety, and combination strategies.

5. What role does regulatory policy play in trabectedin’s market trajectory?

Regulatory agencies in Europe and the US have established pathways for orphan drugs, facilitating market access. Future approvals for additional indications or combination therapies could open new revenue streams. Regulatory variances in emerging markets also influence geographic expansion strategies.

---

Key Takeaways

• Market potential remains strong through expansion of indications, with steady growth projections (CAGR 6.4%).

• Patent expiry in 2024-2025 necessitates strategic planning for biosimilar competition and patent extensions via new indications or orphan designation.

• Geographic expansion, notably in Asia, is critical to offset mature markets’ saturation and maintain growth momentum.

• Pipeline innovation through combination therapies and novel formulations can enhance therapeutic positioning and market share.

• Competitive landscape is evolving rapidly; differentiation hinges on clinical efficacy in resistant subpopulations and strategic partnerships.

---

References

[1] Global Oncology Market Size and Trends (2022). ReportLinker, 2022.

[2] Ovarian Cancer Market Overview (2022). MarketsandMarkets, 2022.